New registry study aims to find best antibody treatment for rare nerve disease
NCT ID NCT06885957
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This registry study is tracking 200 adults in China with a specific type of neuromyelitis optica spectrum disorder (NMOSD) who are receiving monoclonal antibody therapies. The goal is to see how well these treatments prevent relapses and manage symptoms in everyday medical practice. Researchers will also monitor brain scans and immune markers over time to better understand the disease and treatment effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
monoclonal antibody therapy
What this could lead to
If successful, this study could confirm which monoclonal antibody works best for controlling NMOSD relapses in real-world settings, improving long-term disease management.
What could go wrong
This is an observational registry, not a controlled trial, so results may be less definitive. It only includes Chinese adults, so findings may not apply to other populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.